title: Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer.
abstract: OBJECTIVE
  Survival following resection for ampullary carcinoma may be influenced by 1 or more clinical or pathologic variables.
  
  
  METHODS
  Retrospective medical records review.
  
  
  METHODS
  Academic tertiary care center.
  
  
  METHODS
  From July 1, 1991, through April 30, 2004, 72 patients (31 males and 41 females) were treated for ampullary carcinoma at Loyola University Medical Center, Maywood, Ill. Of these, 51 patients who underwent potentially curative pancreaticoduodenectomy were studied.
  
  
  METHODS
  Whipple procedure for attempted cure in 51 patients with ampullary adenocarcinoma.
  
  
  METHODS
  The effects of clinical and pathologic factors on disease-specific survival were analyzed using log-rank and a multivariate Cox proportional hazards model.
  
  
  RESULTS
  The median age of the 51 patients (25 males and 26 females) was 69 years (age range, 38-90 years). Median operative time was 6 hours (range, 4-12 hours), and median estimated blood loss was 800 mL (range, 350-7500 mL). Thirty-day mortality was 2% (1 of 51 patients). Twenty-seven had node-negative disease, 34 cases were T1/T2, and 23 were well differentiated. Median follow-up for patients still alive was 42 months (range, 2-147 months); overall 5-year disease-specific survival was 58%. Five-year survival was 78% (21/27) in node-negative patients, 73% (25/34) for T1/T2 patients, and 76% (17/23) for well-differentiated tumors compared with 25% for node-positive, 8% for T3/T4, and 36% for poorly or moderately differentiated tumors (P<.01). On multivariate analysis, only node-negative disease maintained significance (hazard ratio, 5.2; 95% confidence interval, 1.2-21.9). In all groups, there were no deaths due to disease after 3 years of survival was reached.
  
  
  CONCLUSIONS
  Pancreaticoduodenectomy is curative in 80% of patients with node-negative ampullary carcinomas. Once 3-year survival is reached, long-term survival can be expected.
authors.affiliation: Department of Surgery, Section of Surgical Oncology, Loyola University Medical Center, Maywood, IL 60153, USA.
authors.forename: Kimberly M
authors.initials: KM
authors.lastname: Brown
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Tompkins
authors.forename: Sherri
authors.initials: S
authors.lastname: Yong
authors.forename: Gerard V
authors.initials: GV
authors.lastname: Aranha
authors.forename: Margo
authors.initials: M
authors.lastname: Shoup
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014670:Ampulla of Vater; D016063:Blood Loss, Surgical; D003138:Common Bile Duct Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016577:Pancreaticoduodenectomy; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome